Please choose your application, enter the information requested below. * Marked fields are mandatory.
Product Description
Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor with IC50 of 5.22 nM.
IC50 & Target: IC50: 5.22 nM (PDE 5)[1]
In Vitro: Pretreatment with 1 μM Sildenafil potentiates the phosphorylation of ERK1/ERK2, an increase in the percentage of cells in S phase and cell proliferation, compared with serotonin stimulation alone (P<0.05). Pretreatment with 1 μM Sildenafil citrate followed by serotonin stimulation leads to dramatic increase in OD value to 0.33, significantly different compared with serotonin stimulation alone (P<0.05). 1 μM Sildenafil obviously enhances the upregulation of ERK1/ERK2 phosphorylation induced by serotonin[2].
In Vivo: In the dog model of erection, Sildenafil citrate significantly increases ICP and ICP/BP but shows no significant effect on BP compared with vehicle[1]. Sildenafil treatment significantly decreases the number of TL+-cells at 10 but not 0.5 mg/kg. At this time point, cells positive for the M1-like marker COX-2+ are found in the ischemic core in PBS-treated animals, whereas they are mostly observed in the penumbra in 10 mg/kg (but not 0.5 mg/kg) Sildenafil-treated animals. In contrast, 8 days after pMCAo the number of microglia/macrophages stained by Iba-1 are significantly reduced by Sildenafil treatment (0.5 and/or 10 mg/kg dose)[3]. Sildenafil citrate has been reported to decrease flap necrosis in preclinical animal models by increasing the secretion of growth factors (FGF and VEGF), and histologically is shown to be effective in rat cavernous nerve architecture[4].
Information
CAS No139755-83-2
FormulaC22H30N6O4S
Clinical Informationclinicalinformation
PathwayMetabolic Enzyme/Protease Autophagy
TargetPhosphodiesterase (PDE) Autophagy
Specifications
Purity / Grade>98%
SolubilityDMSO : ≥ 29 mg/mL (61.11 mM)
Smilessmiles
Misc Information
Alternative NamesUK-92480
Observed Molecular Weight474.58
related data
Get valuable resources and offers directly to your email.